封面
市场调查报告书
商品编码
1544105

胚胎着床前遗传学诊断(PGD)的全球市场

Preimplantation Genetic Diagnosis (PGD)

出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 173 Pages | 商品交期: 最快1-2个工作天内

价格

本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

到2030年,全球胚胎着床前遗传学诊断(PGD)市场预计将达到1.604亿美元

2023年全球胚胎着床前遗传学诊断(PGD)市场预计为1.149亿美元,预计到2030年将达到1.604亿美元,2023-2030年分析期间复合年增长率为4.9%。染色体异常是本报告分析的细分市场之一,预计复合年增长率为 4.2%,到分析期结束时将达到 3,360 万美元。在分析期间,非整倍体部分的复合年增长率估计为 4.5%。

美国市场预估为3,060万美元,中国预期复合年增长率为7.2%

预计2023年美国胚胎着床前遗传学诊断(PGD)市场规模将达3,060万美元。中国作为世界第二大经济体,预计2030年市场规模将达3,460万美元,2023-2030年分析期间复合年增长率为7.2%。其他值得注意的区域市场包括日本和加拿大,在分析期间预计复合年增长率分别为 2.7% 和 4.3%。在欧洲,德国的复合年增长率预计为 2.9%。

全球胚胎着床前基因诊断 (PGD) 市场 - 主要趋势和驱动因素总结

胚胎着床前遗传学诊断 (PGD):保护您的遗传健康

胚胎着床前遗传学诊断(PGD)是一种与体外受精(IVF)结合使用的特殊程序,用于在胚胎植入子宫之前筛检胚胎是否有遗传异常。这项技术可以让有遗传性疾病或染色体异常病史的夫妻降低将其遗传给后代的风险。 PGD​​ 涉及对发育中胚胎的一个或多个细胞切片检查,通常在受精后 3 至 5 天进行,然后进行基因分析以检测特定突变或染色体异常。仅选择没有遗传异常的胚胎进行植入,增加健康怀孕的机会并降低遗传疾病的风险。 PGD​​对于囊肿纤维化、亨廷顿病和镰状细胞性贫血等遗传性疾病携带者的夫妇尤其有价值,因为它为生殖过程提供了额外的安全保障。

科技进步如何改善胚胎着床前遗传学诊断 (PGD)?

技术进步显着提高了胚胎着床前遗传学诊断(PGD)的准确性、可靠性和范围。次世代定序仪(NGS) 的出现彻底改变了 PGD,能够对整个基因组进行全面分析,从而能够更准确地检测更广泛的遗传异常。该技术还减少了基因分析所需的时间,并能够在 IVF 过程中快速做出决策。更复杂的切片检查技术的发展,例如第5天胚胎的体外切片检查,将提高PGD的安全性和有效性,并将对胚胎造成伤害的风险降至最低,同时允许更大、更具代表性的样本。此外,生物资讯学和资料分析的进步正在增强对遗传资料的解释,并为胚胎的遗传健康提供更准确和详细的见解。这些技术进步拓宽了PGD的应用范围,使其成为确保子孙后代遗传健康的更强有力的工具。

胚胎着床前遗传学诊断(PGD)的主要用途和好处是什么?

胚胎着床前遗传学诊断(PGD)可用于各种生殖环境,并具有许多好处,可增加健康怀孕的机会并降低遗传性疾病的风险。如果父母一方或双方都是已知基因突变的携带者,PGD可以选择不携带该突变的胚胎,从而大大降低将其遗传给孩子的风险。 PGD​​ 还可以帮助识别染色体异常的胚胎,这些异常不太可能成功怀孕。此外,PGD 对于接受 IVF 的老年女性很有价值,因为它可以筛检与老龄化相关的染色体异常,例如唐氏症,从而增加健康怀孕的机会。 PGD​​的主要好处是可以降低遗传疾病的风险,提高试管婴儿的成功率,让准父母安心。透过选择遗传健康的胚胎,PGD 可以增强生殖过程,并有助于子孙后代的长期健康。

胚胎着床前遗传学诊断(PGD)市场成长的因素有哪些?

胚胎着床前遗传学诊断(PGD)市场的成长受到多种因素的推动。遗传病患病率的不断上升以及人们对生殖医学中基因筛检益处的认识不断提高是重要的驱动因素。此外,提高 PGD 准确性、安全性和可近性的技术进步也推动了市场成长。对 IVF 的需求不断增长,尤其是老年女性和有遗传病史的夫妇,进一步推动了 PGD 的采用。此外,扩大遗传咨询服务以指导夫妻完成 PGD 过程也有助于市场成长。先进基因检测技术的日益普及以及对个人化医疗的日益关注正在进一步推动市场发展。这些因素,加上生殖遗传学领域持续的技术创新,正在推动 PGD 市场的持续成长。

受访企业范例(46家知名企业)

  • Abbott Laboratories
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings(LabCorp)
  • Natera, Inc.
  • PerkinElmer, Inc.

目录

第一章调查方法

第 2 章执行摘要

  • 市场概况
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他中东地区
  • 非洲

第四章 比赛

简介目录
Product Code: MCP14183

Global Preimplantation Genetic Diagnosis (PGD) Market to Reach US$160.4 Million by 2030

The global market for Preimplantation Genetic Diagnosis (PGD) estimated at US$114.9 Million in the year 2023, is expected to reach US$160.4 Million by 2030, growing at a CAGR of 4.9% over the analysis period 2023-2030. Chromosomal Abnormalities, one of the segments analyzed in the report, is expected to record a 4.2% CAGR and reach US$33.6 Million by the end of the analysis period. Growth in the Aneuploidy segment is estimated at 4.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$30.6 Million While China is Forecast to Grow at 7.2% CAGR

The Preimplantation Genetic Diagnosis (PGD) market in the U.S. is estimated at US$30.6 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$34.6 Million by the year 2030 trailing a CAGR of 7.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 4.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR.

Global Preimplantation Genetic Diagnosis (PGD) Market - Key Trends and Drivers Summarized

Preimplantation Genetic Diagnosis (PGD): Safeguarding Genetic Health

Preimplantation genetic diagnosis (PGD) is a specialized procedure used in conjunction with in vitro fertilization (IVF) to screen embryos for genetic abnormalities before they are implanted in the uterus. This technique allows couples with a history of genetic disorders or chromosomal abnormalities to reduce the risk of passing these conditions on to their offspring. PGD involves the biopsy of one or more cells from a developing embryo, typically on the third or fifth day after fertilization, followed by genetic analysis to detect specific mutations or chromosomal abnormalities. Only embryos that are free of genetic defects are selected for implantation, increasing the likelihood of a healthy pregnancy and reducing the risk of genetic diseases. PGD is particularly valuable for couples who are carriers of hereditary conditions such as cystic fibrosis, Huntington's disease, or sickle cell anemia, as it provides an additional layer of assurance in the reproductive process.

How Are Technological Advancements Enhancing Preimplantation Genetic Diagnosis (PGD)?

Technological advancements have significantly improved the accuracy, reliability, and scope of preimplantation genetic diagnosis (PGD). The advent of next-generation sequencing (NGS) has revolutionized PGD by allowing comprehensive analysis of the entire genome, enabling the detection of a broader range of genetic abnormalities with greater precision. This technology has also reduced the time required for genetic analysis, allowing for faster decision-making in the IVF process. The development of more sophisticated biopsy techniques, such as trophectoderm biopsy on day five embryos, has increased the safety and effectiveness of PGD, minimizing the risk of harm to the embryo while providing a larger and more representative sample for analysis. Additionally, advances in bioinformatics and data analysis have enhanced the interpretation of genetic data, providing more accurate and detailed insights into the genetic health of embryos. These technological improvements have expanded the applications of PGD, making it a more powerful tool for ensuring the genetic health of future generations.

What Are the Key Applications and Benefits of Preimplantation Genetic Diagnosis (PGD)?

Preimplantation genetic diagnosis (PGD) is used in various reproductive scenarios, offering numerous benefits that enhance the likelihood of a healthy pregnancy and reduce the risk of genetic disorders. In cases where one or both parents are carriers of a known genetic mutation, PGD allows for the selection of embryos that do not carry the mutation, significantly reducing the risk of passing the condition on to the child. PGD is also used in cases of recurrent pregnancy loss, where it helps identify embryos with chromosomal abnormalities that are less likely to result in a successful pregnancy. Additionally, PGD is valuable for older women undergoing IVF, as it can screen for age-related chromosomal abnormalities, such as Down syndrome, improving the chances of a healthy pregnancy. The primary benefits of PGD include its ability to reduce the risk of genetic diseases, increase the success rate of IVF, and provide peace of mind to prospective parents. By allowing for the selection of genetically healthy embryos, PGD enhances the reproductive process and contributes to the long-term health of future generations.

What Factors Are Driving the Growth in the Preimplantation Genetic Diagnosis (PGD) Market?

The growth in the preimplantation genetic diagnosis (PGD) market is driven by several factors. The increasing prevalence of genetic disorders and the growing awareness of the benefits of genetic screening in reproductive health are significant drivers. Technological advancements that improve the accuracy, safety, and accessibility of PGD are also propelling market growth. The rising demand for IVF procedures, particularly among older women and couples with a history of genetic disorders, is further boosting the adoption of PGD. Additionally, the expansion of genetic counseling services, which guide couples through the PGD process, is contributing to market growth. The increasing availability of advanced genetic testing technologies and the growing focus on personalized medicine are further driving the market. These factors, combined with the continuous innovation in reproductive genetics, are driving the sustained growth of the PGD market.

Select Competitors (Total 46 Featured) -

  • Abbott Laboratories
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings (LabCorp)
  • Natera, Inc.
  • PerkinElmer, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Preimplantation Genetic Diagnosis (PGD) - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Genetic Disease Prevention Drives Market Growth
    • Technological Advancements in Genetic Testing Propel Market Dynamics
    • Increasing Awareness of Reproductive Health and Genetic Disorders Expands Addressable Market
    • Growing Adoption of In-vitro Fertilization (IVF) Techniques Throws the Spotlight on PGD
    • Focus on Reducing Risk of Genetic Disorders Enhances Market Prospects
    • Increasing Number of Fertility Clinics and Genetic Counseling Centers Boosts Market Reach
    • Expansion of Personalized Medicine and Precision Healthcare Sustains Market Growth
    • Rising Demand for Gender Selection and Family Balancing Accelerates Market Dynamics
    • Growing Awareness of Late Maternal Age and Associated Risks Spurs Market Demand
    • Collaborations between Research Institutes and Healthcare Providers Generate Innovation
    • Advancements in Genomic Technologies and Bioinformatics Propel Market Expansion
    • Focus on Ethical and Regulatory Compliance Enhances Market Opportunities
    • Increasing Healthcare Expenditure and Insurance Coverage Expands Market Reach
    • Rising Number of Fertility Treatments and Success Rates Boost Market Prospects
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 2: World 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2024 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for Chromosomal Abnormalities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 4: World 7-Year Perspective for Chromosomal Abnormalities by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Aneuploidy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 6: World 7-Year Perspective for Aneuploidy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for X-linked Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 8: World 7-Year Perspective for X-linked Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
    • TABLE 9: World Recent Past, Current & Future Analysis for Single Gene Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 10: World 7-Year Perspective for Single Gene Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for HLA Typing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 12: World 7-Year Perspective for HLA Typing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Gender selection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 14: World 7-Year Perspective for Gender selection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
    • TABLE 15: World Recent Past, Current & Future Analysis for Other PGD Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 16: World 7-Year Perspective for Other PGD Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
    • TABLE 17: World Preimplantation Genetic Diagnosis (PGD) Market Analysis of Annual Sales in US$ for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 18: USA Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 19: USA 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • CANADA
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Canada 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • JAPAN
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 22: Japan Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 23: Japan 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • CHINA
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 24: China Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 25: China 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • EUROPE
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 27: Europe 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2024 & 2030
    • TABLE 28: Europe Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 29: Europe 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • FRANCE
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 30: France Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 31: France 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • GERMANY
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 32: Germany Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Germany 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • ITALY
    • TABLE 34: Italy Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 35: Italy 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • UNITED KINGDOM
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 36: UK Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 37: UK 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • SPAIN
    • TABLE 38: Spain Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Spain 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • RUSSIA
    • TABLE 40: Russia Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 41: Russia 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • REST OF EUROPE
    • TABLE 42: Rest of Europe Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 43: Rest of Europe 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • ASIA-PACIFIC
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 44: Asia-Pacific Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 45: Asia-Pacific 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2024 & 2030
    • TABLE 46: Asia-Pacific Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 47: Asia-Pacific 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • AUSTRALIA
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 48: Australia Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 49: Australia 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • INDIA
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 50: India Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 51: India 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • SOUTH KOREA
    • TABLE 52: South Korea Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 53: South Korea 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 54: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 55: Rest of Asia-Pacific 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • LATIN AMERICA
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 56: Latin America Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 57: Latin America 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2024 & 2030
    • TABLE 58: Latin America Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 59: Latin America 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • ARGENTINA
    • TABLE 60: Argentina Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 61: Argentina 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • BRAZIL
    • TABLE 62: Brazil Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Brazil 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • MEXICO
    • TABLE 64: Mexico Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 65: Mexico 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 66: Rest of Latin America Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 67: Rest of Latin America 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • MIDDLE EAST
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 68: Middle East Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 69: Middle East 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2024 & 2030
    • TABLE 70: Middle East Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 71: Middle East 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • IRAN
    • TABLE 72: Iran Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 73: Iran 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • ISRAEL
    • TABLE 74: Israel Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Israel 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • SAUDI ARABIA
    • TABLE 76: Saudi Arabia Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 77: Saudi Arabia 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 78: UAE Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 79: UAE 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 80: Rest of Middle East Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Rest of Middle East 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • AFRICA
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 82: Africa Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 83: Africa 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030

IV. COMPETITION